# Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

> **NCT02405585** · PHASE2 · TERMINATED · sponsor: **NewLink Genetics Corporation** · enrollment: 10 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Carcinoma Non-resectable

## Interventions

- **DRUG:** mFOLFIRINOX
- **BIOLOGICAL:** Algenpantucel-L Immunotherapy
- **RADIATION:** SBRT
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02405585
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2016-06-30
- **Final completion:** 2016-07-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405585, "Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02405585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*